Supplementary Table 1. Cat demographics and disease status before treatment

Cat#	Age at disease onset, months	Sex[1]	Breed	Duration[2], days	FIP type	Pyogranulomatous lesions	Neurological or ocular clinical signs	Presumptive diagnosis by viral RNA detection (sample type)
1	10	MN	Domestic mixed-breed	4	Effusive	N	N	+ (abdominal effusion)*
2	8	FN	Domestic mixed-breed	22	Effusive	N	N	+ (abdominal effusion)*
3	3	ME	Exotic Shorthair	7	Effusive	N	N	+ (abdominal effusion)*
4	6	FF	Somali	7	Effusive	N	N	+ (abdominal effusion)*
5	44	ME	Siberian	20	Effusive	N	N	+ (abdominal effusion)*
6	38	FN	Russian Blue	42	Effusive	1cm in the abdominal cavity	N	+ (abdominal effusion)*
7	8	FN	Domestic mixed-breed	49	Non-effusive	N	N	+ (whole blood)*
8	17	MN	British Shorthair	6	Non-effusive	3cm in the abdominal cavity	seizure neurologic symptoms	+ (FNA of pyogranulomatous lesions)*
9	3	MN	Norwegian Forest	2	Effusive	N	N	+ (abdominal effusion)*

10	6	ME	Domestic mixed-breed	8	Non-effusive	N	postural reflexes blunting	+ (whole blood)**
11	7	FN	Domestic mixed-breed	7	Effusive	N	N	None
12	4	MN	Munchkin	8	Effusive	N	N	+ (abdominal effusion)*
13	3	ME	British Shorthair	28	Effusive	N	N	+ (abdominal effusion)*
14	6	FE	Domestic mixed-breed	23	Effusive	0.7cm in the abdominal cavity	N	+ (pleural effusion)*
15	28	ME	Domestic mixed-breed	30	Non-effusive	N (enlarged kidney on US)	N	+ (whole blood)**
16	4	ME	Exotic Shorthair	28	Effusive	N	N	+ (abdominal effusion)*
17	5	ME	Domestic mixed-breed	13	Effusive	2cm in the abdominal cavity	N	+ (abdominal effusion)*
18	93	FN	Domestic mixed-breed	40	Non-effusive	3cm in the abdominal cavity	Abnormal pupillary reflex	+ (FNA of pyogranulomatous lesions)*

Abbreviations: FNA, fine needle aspirate (of effusion); PCR, polymerase chain reaction; US, ultrasound

[1] FE, Female entire (unspayed); FN, female neutered (spayed); ME, Male entire (uncastrated); MN, male neutered (castrated).

[2] Duration from the disease onset to the treatment start, based on owner's report of when signs first appeared.

* PCR was performed at IDEXX Laboratories.

** PCR was performed at Canine-Lab Corp.

Supplementary Table 2. Summary of treatment courses

Cat #	Dose, mg/kg BID	Outcomes	Date of the final test on which the treatment discontinuation decision was made	Total days of molnupiravir administration	Days without recurrence after the final administration	Findings during treatment	Adverse events
1	20 → 40 from day 8	Remission	84	99	107	Disturbed consciousness was found at day 8 and dose increased from 20 to 40 mg/kg	None
2	30	Died on day 6	_	6	_		–
3	20 → 30 from day14	Remission	70	84	99	A 2 cm granulomatous change in the abdominal cavity on day14	None
4	20	Remission	71	84	92		None
5	20	Remission	70	84	85		None
6	30	Remission	72	84	86		None
7	30 → 40 from day 15	Remission	77	84	74	Asymmetric pupil dilation occurred on day2	None

8	30	Remission	70	84	72		Developed jaundice on day 37 → hospitalized for 3 days
9	20	Remission	71	84	72		Elevated ALT value[1] on day 7 (recovered without management)
10	40	Remission	70	84	71	Blunted postural reflexes	Elevated ALT value[1] on day 7 (recovered without management)
11	40	Died on day 1	_	1	_		–
12	20→40 from day 7	Remission	70	84	67	Convulsive seizure on day 7	None
13	20	Euthanized on day 6	_	6	_		–
14	30	Remission	65	84	57		None
15	30	Remission	73	84	57	Hospitalized 5 days on days 1–5 for anemia and jaundice	None
16	30	Died on day 6	_	6	_		–
17	40	Remission	69	84	55		Elevated ALT value[1] on day 9 (recovered without management)
18	40	Remission	70	84	60		None

Abbreviation: ALT, Alanine transaminase.

[1] Reference interval 12 - 130 U/L

Supplementary Table 3. Test values obtained on the first visit and the final test on which the treatment discontinuation decision made

CAT #	Body temperature, ℃		Body weight, kg		HCT, %[1]		Albumin/Globulin ratio[2]		α1AG, μg/mL[3]	
	1st visit[4]	Last test before treatment discontinuation	1st visit[4]	Last test before treatment discontinuation	1st visit[4]	Last test before treatment discontinuation	1st visit[4]	Last test before treatment discontinuation	1st visit[4]	Last test before treatment discontinuation
1	38.4	37.3	3.4	4.45	28.7	48.37	0.43	0.43	>2000	725
2	40	_	2.5	_	24.1	_	0.36	_	>2000	_
3	39.5	38.5	1.5	2.4	24.1	34.1	0.29	0.71	>2000	427
4	38.5	38.3	1.8	2.18	16.4	37	0.16	0.6	>2000	336
5	38.3	38.3	3.3	3.94	24.3	57.8	0.4	0.66	>2000	489
6	39	38.3	2.8	3.5	21	43.9	0.28	0.28	>2000	325
7	38.9	38.5	3.3	4.29	51.4	48.3	0.55	0.6	>2000	480
8	39.8	38.6	3.5	3.65	31.3	41	0.41	1.01	>2000	449
9	39.1	38.4	1.7	2.82	25.4	35.3	0.38	0.75	>2000	304
10	41	38.6	2.4	3.55	28.1	46.9	0.34	0.53	>2000	548
11	39.7	_	1.5	_	18	_	0.35	_	>2000	_

12	38.4	38.5	4.2	4.4	24.1	36	0.40	0.6	>2000	464
13	39.9	_	2.8	_	20.2	_	0.25	_	>2000	_
14	38.6	38.6	3.1	3.5	32	39.3	0.37	0.76	>2000	545
15	41	38.5	3.3	3.86	24.5	46	0.46	0.65	>2000	397
16	40	_	2.1	_	26.8	_	0.29	_	>2000	_
17	40.1	38.2	2.7	4	30.5	43	0.43	0.63	>2000	437
18	38.5	36.4	3.1	3.06	30.1	42.8	0.19	0.68	>2000	667

***Abbreviations**:* α1AG, α1acid glycoprotein; HCT, hematocrit.

[1] Reference interval 30.3 - 52.3% (IDEXX Laboratories)

[2] Reference interval 0.6 – 1.32 (Fujifilm VET Systems)

[3] Reference interval 0 - 736 µg/mL (Fujifilm VET Systems)

[4]Date on which presumptive FIP diagnosis was made and molnupiravir initiated.